Table 1.

Incidence and risk of breast and/or ovarian cancer in the prospective study according to genotype

Participants (n)Breast and/or ovarian cancers (n)Incidence (95% CI; per 10,000 person-year)Log-rank PHazard ratio (95% CI)80% power hazard ratio*
Age adjustmentMultifactorial adjustment
BRCA1
    Gln356Arg
        Gln-Gln4,97635621 (19-23)1.01.0
        Gln-Arg6866025 (20-33)0.061.3 (1.0-1.7)1.1 (0.9-1.5)1.4
        Arg-Arg21339 (13-121)0.072.7 (0.9-8.5)2.2 (0.7-6.9)3.3
    Pro871Leu
        Pro-Pro2,44318322 (19-25)1.01.0
        Pro-Leu2,58218921 (19-25)0.911.0 (0.8-1.2)1.0 (0.8-1.2)1.3
        Leu-Leu6574721 (16-28)0.921.0 (0.7-1.4)1.0 (0.7-1.4)1.5
    Glu1038Gly
        Glu-Glu2,57819422 (19-25)1.01.0
        Glu-Gly2,49818321 (19-25)0.891.0 (0.8-1.2)1.0 (0.8-1.2)1.3
        Gly-Gly6074220 (15-28)0.750.9 (0.7-1.3)0.9 (0.7-1.3)1.5
    Ser1613Gly
        Ser-Ser2,57119322 (19-25)1.01.0
        Ser-Gly2,49818221 (18-25)0.841.0 (0.8-1.2)1.0 (0.8-1.2)1.3
        Gly-Gly6144421 (16-28)0.891.0 (0.7-1.4)1.0 (0.7-1.3)1.5
    Met1652Ile
        Met-Met5,54740721 (19-24)1.01.0
    Met-Ile +     Ile-Ile1371226 (15-46)0.451.3 (0.7-2.2)1.3 (0.7-2.4)1.9
BRCA2
    Asn289His
        Asn-Asn 5,35139021 (19-24)1.01.0
    Asn-His +     His-His3332925 (18-36)0.641.1 (0.7-1.6)1.1 (0.8-1.6)1.6
    Asn372His
        Asn-Asn2,92120721 (18-24)1.01.0
        Asn-His2,32217923 (19-26)0.781.0 (0.8-1.3)1.0 (0.9-1.3)1.3
        His-His4403322 (15-30)0.751.1 (0.7-1.5)0.9 (0.6-1.4)1.6
    Asp1420Tyr
        Asp-Asp 5,54241022 (20-24)1.01.0
        Asp-Tyr + Tyr-Tyr142919 (10-36)0.810.9 (0.5-1.8)0.8 (0.4-1.7)1.9
    Tyr1915Met
        Tyr-Tyr5,31739622 (20-24)1.01.0
    Tyr-Met + Met-Met3672319 (12-28)0.690.9 (0.6-1.4)0.9 (0.6-1.4)1.6

NOTE: Multifactorial adjustment included age (<50 y vs ≥50 y), body mass index (BMI ≤25 kg/m2 vs 25 kg/m2 < BMI ≤30 kg/m2 vs BMI >30 kg/m2), weekly alcohol intake (0 grams/wk vs 1-168 grams/wk vs >168 grams/wk), parity (number of children), nulliparity (yes/no), use of oral contraceptive drugs at the time of examination (yes/no), menopausal status (premenopausal/postmenopausal), and use of hormonal replacement therapy at the time of examination (yes/no).

Abbreviation: CI, confidence interval.

  • *We had 80% power at two-sided P value of <0.05 to exclude the hazard ratios given.

  • Homozygotes were pooled with heterozygotes in analyses of polymorphisms with a MAF of <5%.